Refine
Has Fulltext
- yes (98)
Is part of the Bibliography
- yes (98)
Year of publication
- 2015 (98) (remove)
Document Type
- Journal article (61)
- Doctoral Thesis (37)
Keywords
- cancer (4)
- membrane proteins (4)
- Aspergillus fumigatus (3)
- Vaccinia-Virus (3)
- biodiversity (3)
- gene (3)
- honeybee (3)
- in vitro (3)
- mushroom body (3)
- olfaction (3)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (98) (remove)
Sonstige beteiligte Institutionen
ResearcherID
- D-1221-2009 (1)
- N-2030-2015 (1)
Die klinische Symptomatik verschiedener erblicher Muskelerkrankungen verläuft oft erstaunlich ähnlich mit Muskelschwäche und -schwund als den hervorstechenden Alltagsproblemen. Dem gegenüber sind die genetischen Grundlagen sehr vielfältig mit > 250 bisher identifizierten Genen (musclegenetable.org). Auch innerhalb eines definierten Krankheitsbildes werden verschiedene genetische Ursachen nebeneinander gefunden, was durch die Verknüpfung in einem gemeinsamen Pathomechanismus begründet sein kann. Die vorliegende Arbeit beschäftigt sich mit verschiedenen Aspekten dieser genetischen Heterogenität am Beispiel der beiden häufigen Muskelerkrankungen Myotone Dystrophie (DM) und Facioscapulohumerale Muskeldystrophie (FSHD), bei denen alternative genetische Ursachen, sowie anknüpfende Fragestellungen untersucht wurden.
Das erste Projekt dieser Arbeit beschäftigt sich mit Fragestellungen, welche die DM betreffen. Die DM Typ 1 und Typ 2 (DM1 und DM2) bilden zusammen die häufigste Muskelerkrankung im Erwachsenenalter. Sie ist durch die gemeinsamen Symptome Myotonie, Muskelschwäche und Katarakt sowie die Beteiligung weiterer Organsysteme gekennzeichnet, was sie zu einer multisystemischen Erkrankung macht. Die genetische Ursache liegt für beide Formen in einer Repeatexpansion eines Mikrosatelliten in der untranslatierten Region zweier Gene (DMPK in DM1, CNBP in DM2). Dem gemeinsamen Pathomechanismus liegt eine toxische Funktionsgewinn-Mutation des expandierten RNA-Transkripts zugrunde.
Die beiden bekannten Formen der DM sind phänotypisch häufig nicht unterscheidbar, weshalb in vielen Fällen beide Erkrankungen molekulargenetisch untersucht werden müssen. Dabei ist die Diagnostik der DM durch die Notwendigkeit des Nachweises von sehr großen Repeatexpansionen recht aufwändig und die Bestimmung der Repeatlänge im Fall der DM2 nur eingeschränkt möglich. Im Rahmen dieser Arbeit wurde ein Test zum Nachweis der Repeatexpansionen auf der Basis der Methode des Molecular Combing entwickelt, welche den gleichzeitigen Nachweis der beiden Loci von DM1 und DM2 erlaubt und zusätzlich eine direkte Messung der Repeatlänge ermöglicht. Das Molecular Combing ist eine fluoreszenz-mikroskopische Einzelmolekül-Analysemethode, durch die es erstmals möglich wurde, die vermutete somatische Instabilität bei DM2 darzustellen.
Das zweite DM-Teilprojekt beschäftigt sich mit der Identifikation möglicher alternativer genetischer Ursachen für die Erkrankung. Dies wurde anhand einer Kohorte von 138 DM1- und DM2-negativen Indexpatienten mit dem typischen DM-Phänotyp untersucht. Ausgehend von dem gemeinsamen Pathomechanismus wurden die primären Krankheitsgene DMPK und CNBP, sowie CELF1 und MBNL1, welche wichtige Rollen auf sekundärer Ebene des Pathomechanismus spielen, mittels Next Generation Sequencing untersucht. Dabei wurde eine auffällige Variante in DMPK gefunden, keine Varianten in CNBP oder CELF1 und drei Varianten in MBNL1, was auf MBNL1 als Kandidatengen einer alternativen Ursache für DM hinweist. MBNL1 ist ein gewebespezifischer Spleißregulator, welcher einen Wechsel von einem fetalen zu einem adulten Spleißmuster im Muskel steuert. Die Pathogenität einer der Varianten wurde in einem RNA-Spleißassay mit MBNL1-Targetgenen untersucht. Dabei konnten keine spezifischen Spleiß-Effekte festgestellt werden, aber eine Verminderung des Expressionsniveaus im Sinne einer Haploinsuffizienz. Die 3D-Modellierung dieser Variante deutet auf Änderungen der Oberflächenladungen in MBNL1 hin. Der Nachweis der Pathogenität der Varianten und somit die Ursächlichkeit von MBNL1-Mutationen für DM konnte hiermit nicht abschließend geklärt werden. Die gefundenen Ergebnisse regen jedoch hoffentlich zu nachfolgenden Studien an.
Das zweite Projekt dieser Arbeit beschäftigt sich mit Fragestellungen um die FSHD. Diese bildet die dritthäufigste Muskelerkrankung, charakterisiert durch eine oft asymmetrische Schwäche der Muskulatur von Gesicht, Schultergürtel und Oberarmen. Genetisch ist die FSHD Typ 1 (FSHD1) mit einer Kontraktion des Makrosatelliten D4Z4 verknüpft, was eine Relaxation der Chromatinstruktur der Region mit sich bringt und damit die ektopische Expression des apoptotisch wirkenden Proteins DUX4 ermöglicht. Die pathogene Ausprägung dieser Funktionsgewinn-Mutation findet dabei nur in Verbindung mit einem FSHD-permissiven Haplotyp statt.
Auf der Grundlage des gleichen Pathomechanismus wurde eine zweite Form der FSHD (FSHD2) vorgestellt, bei der die Chromatinrelaxation unabhängig von der Länge von D4Z4 durch einen Defekt in dem an der DNA-Methylierung beteiligten Gen SMCHD1 assoziiert sein soll. Die Vererbung von FSHD2 verläuft digenisch mit Mutationen in SMCHD1 und dem FSHD-permissiven Haplotyp auf zwei unabhängigen Loci. Im Rahmen dieser Arbeit wurde eine Kohorte von 55 FSHD1-negativen Patienten mit dem typischen FSHD-Phänotyp untersucht. Dabei wurden der Haplotyp, die Methylierung von D4Z4 sowie das SMCHD1-Gen analysiert. Es konnten neun Patienten mit einem Defekt in SMCHD1 identifiziert werden. In einer zweiten Kohorte von 45 FSHD1-positiven Patienten wurde untersucht, ob SMCHD1-Mutationen auch in Kombination mit einer Kontraktion von D4Z4 vorkommen. Dieser Fall von FSHD1+2 konnte für drei Patienten gezeigt werden, welche außerdem einen auffällig schweren Phänotyp zeigten. SMCHD1 kann also als Modifier-Gen für die Schwere der Erkrankung bei FSHD1 angesehen werden. Damit wurden insgesamt zwölf SMCHD1-Mutationsträger identifiziert, davon sind zehn der Varianten noch nicht beschrieben worden. Für alle erkrankten Mutationsträger konnte eine Methylierung von D4Z4 ≤ 20 % ermittelt werden, was als diagnostisches Kriterium verwendet werden kann. Mit einem Anteil von 16,3 % Mutationsträger in der FSHD1-negetiven Kohorte bildet FSHD2 einen bedeutenden Anteil an dem Krankheitsbild der FSHD, weshalb die entwickelten Analysen in die Routinediagnostik eingegliedert wurden.
Das zweite Teilprojekt der FSHD beschäftigt sich mit der Funktion des SMCHD1-Gens bei der X-Inaktivierung (XI). Es ist bekannt, dass SMCHD1 bei weiblichen Mäusen an der Aufrechterhaltung der XI mitwirkt. Die Untersuchung der XI bei FSHD2-Frauen ergab eine extreme Verschiebung der erwarteten XI von 50:50 auf 0:100 oder 100:0 bei sechs von 13 Patientinnen. Die übrigen sieben zeigten eine XI im Normalbereich von > 20:80 oder < 80:20. Der Befund der einseitigen Verschiebung könnte auf einen negativen Selektionsdruck gegenüber Zellen mit unvollständiger XI hindeuten. Es wäre interessant zu untersuchen, ob sich der gleiche Effekt auch in einer größeren Kohorte wiederfindet und ob er sich mit der Art der Mutation korrelieren lässt.
The incidence of malignant melanoma continues to increase each year with poor prognosis for survival in many relapse cases. To reverse this trend, whole body response measures are needed to discover collaborative paths to primary and secondary malignancy. Several species of fish provide excellent melanoma models because fish and human melanocytes both appear in the epidermis, and fish and human pigment cell tumors share conserved gene expression signatures. For the first time, we have examined the whole body transcriptome response to invasive melanoma as a prelude to using transcriptome profiling to screen for drugs in a medaka (Oryzias latipes) model. We generated RNA-seq data from whole body RNA isolates for controls and melanoma fish. After testing for differential expression, 396 genes had significantly different expression (adjusted p-value <0.02) in the whole body transcriptome between melanoma and control fish; 379 of these genes were matched to human orthologs with 233 having annotated human gene symbols and 14 matched genes that contain putative deleterious variants in human melanoma at varying levels of recurrence. A detailed canonical pathway evaluation for significant enrichment showed the top scoring pathway to be antigen presentation but also included the expected melanocyte development and pigmentation signaling pathway. Results revealed a profound down-regulation of genes involved in the immune response, especially the innate immune system. We hypothesize that the developing melanoma actively suppresses the immune system responses of the body in reacting to the invasive malignancy, and that this mal-adaptive response contributes to disease progression, a result that suggests our whole-body transcriptomic approach merits further use. In these findings, we also observed novel genes not yet identified in human melanoma expression studies and uncovered known and new candidate drug targets for further testing in this malignant melanoma medaka model.
Tumor-induced angiogenesis is of major interest for oncology research. Vascular endothelial growth factor (VEGF) is the most potent angiogenic factor characterized so far. VEGF blockade was shown to be sufficient for angiogenesis inhibition and subsequent tumor regression in several preclinical tumor models. Bevacizumab was the first treatment targeting specifically tumor-induced angiogenesis through VEGF blockade to be approved by the Food and Drugs Administration (FDA) for cancer treatment. However, after very promising results in preclinical evaluations, VEGF blockade did not show the expected success in patients. Some tumors became resistant to VEGF blockade. Several factors have been accounted responsible, the over-expression of other angiogenic factors, the noxious influence of VEFG blockade on normal tissues, the selection of hypoxia resistant neoplastic cells, the recruitment of hematopoietic progenitor cells and finally the transient nature of angiogenesis inhibition by VEGF blockade. The development of blocking agents against other angiogenic factors like placental growth factor (PlGF) and Angiopoietin-2 (Ang-2) allows the development of an anti-angiogenesis strategy adapted to the profile of the tumor.
Oncolytic virotherapy uses the natural propensity of viruses to colonize tumors to treat cancer. The recombinant vaccinia virus GLV-1h68 was shown to infect, colonize and lyse several tumor types. Its descendant GLV-1h108, expressing an anti-VEGF antibody, was proved in previous studies to inhibit efficiently tumor induced angiogenesis. Additional VACVs expressing single chain antibodies (scAb) antibodies against PlGF and Ang-2 alone or in combination with anti VEGF scAb were designed.
In this study, VACV-mediated anti-angiogenesis treatments have been evaluated in several preclinical tumor models. The efficiency of PlGF blockade, alone or in combination with VEGF, mediated by VACV has been established and confirmed. PlGF inhibition alone or with VEGF reduced tumor burden 5- and 2-folds more efficiently than the control virus, respectively.
Ang-2 blockade efficiency for cancer treatment gave controversial results when tested in different laboratories. Here we demonstrated that unlike VEGF, the success of Ang-2 blockade is not only correlated to the strength of the blockade. A particular balance between Ang-2, VEGF and Ang-1 needs to be induced by the treatment to see a regression of the tumor and an improved survival. We saw that Ang-2 inhibition delayed tumor growth up to 3-folds compared to the control virus. These same viruses induced statistically significant tumor growth delays. This study unveiled the need to establish an angiogenic profile of the tumor to be treated as well as the necessity to better understand the synergic effects of VEGF and Ang-2. In addition angiogenesis inhibition by VACV-mediated PlGF and Ang-2 blockade was able to reduce the number of metastases and migrating tumor cells (even more efficiently than VEGF blockade).
VACV colonization of tumor cells, in vitro, was limited by VEGF, when the use of the anti-VEGF VACV GLV-1h108 drastically improved the colonization efficiency up to 2-fold, 72 hours post-infection. These in vitro data were confirmed by in vivo analysis of tumors. Fourteen days post-treatment, the anti-VEGF virus GLV-1h108 was colonizing 78.8% of the tumors when GLV-1h68 colonization rate was 49.6%. These data confirmed the synergistic effect of VEGF blockade and VACV replication for tumor regression.
Three of the tumor cell lines used to assess VACV-mediated angiogenesis inhibition were found, in certain conditions, to mimic either endothelial cell or pericyte functions, and participate directly to the vascular structure. The expression by these tumor cells of e-selectin, p-selectin, ICAM-1 and VCAM-1, normally expressed on activated endothelial cells, corroborates our findings. These proteins play an important role in immune cell recruitment, and there amount vary in presence of VEGF, PlGF and Ang-2, confirming the involvement of angiogenic factors in the immuno-modulatory abilities of tumors.
In this study VACV-mediated angiogenesis blockade proved its potential as a therapeutic agent able to treat different tumor types and prevent resistance observed during bevacizumab treatment by acting on different factors. First, the expression of several antibodies by VACV would prevent another angiogenic factor to take over VEGF and stimulate angiogenesis. Then, the ability of VACV to infect tumor cells would prevent them to form blood vessel-like structures to sustain tumor growth, and the localized delivery of the antibody would decrease the risk of adverse effects. Next, the blockade of angiogenic factors would improve VACV replication and decrease the immune-modulatory effect of tumors. Finally the fact that angiogenesis blockade lasts until total regression of the tumor would prevent the recovery of the tumor-associated vasculature and the relapse of patients.
Introduction The fast, precise, and accurate measurement of the new generation of oral anticoagulants such as dabigatran and rivaroxaban in patients' plasma my provide important information in different clinical circumstances such as in the case of suspicion of overdose, when patients switch from existing oral anticoagulant, in patients with hepatic or renal impairment, by concomitant use of interaction drugs, or to assess anticoagulant concentration in patients' blood before major surgery. Methods Here, we describe a quick and precise method to measure the coagulation inhibitors dabigatran and rivaroxaban using ultra-performance liquid chromatography electrospray ionization-tandem mass spectrometry in multiple reactions monitoring (MRM) mode (UPLC-MRM MS). Internal standards (ISs) were added to the sample and after protein precipitation; the sample was separated on a reverse phase column. After ionization of the analytes the ions were detected using electrospray ionization-tandem mass spectrometry. Run time was 2.5 minutes per injection. Ion suppression was characterized by means of post-column infusion. Results The calibration curves of dabigatran and rivaroxaban were linear over the working range between 0.8 and 800 mu g/L (r > 0.99). Limits of detection (LOD) in the plasma matrix were 0.21 mu g/L for dabigatran and 0.34 mu g/L for rivaroxaban, and lower limits of quantification (LLOQ) in the plasma matrix were 0.46 mu g/L for dabigatran and 0.54 mu g/L for rivaroxaban. The intraassay coefficients of variation (CVs) for dabigatran and rivaroxaban were < 4% and 6%; respectively, the interassay CVs were < 6% for dabigatran and < 9% for rivaroxaban. Inaccuracy was < 5% for both substances. The mean recovery was 104.5% (range 83.8-113.0%) for dabigatran and 87.0%(range 73.6-105.4%) for rivaroxaban. No significant ion suppressions were detected at the elution times of dabigatran or rivaroxaban. Both coagulation inhibitors were stable in citrate plasma at -20 degrees C, 4 degrees C and even at RT for at least one week. A method comparison between our UPLC-MRM MS method, the commercially available automated Direct Thrombin Inhibitor assay (DTI assay) for dabigatran measurement from CoaChrom Diagnostica, as well as the automated anti-Xa assay for rivaroxaban measurement from Chromogenix both performed by ACL-TOP showed a high degree of correlation. However, UPLC-MRM MS measurement of dabigatran and rivaroxaban has a much better selectivity than classical functional assays measuring activities of various coagulation factors which are susceptible to interference by other coagulant drugs. Conclusions Overall, we developed and validated a sensitive and specific UPLC-MRM MS assay for the quick and specific measurement of dabigatran and rivaroxaban in human plasma.
Swords are exaggerated male ornaments of swordtail fishes that have been of great interest to evolutionary biologists ever since Darwin described them in the Descent of Man (1871). They are a novel sexually selected trait derived from modified ventral caudal fin rays and are only found in the genus Xiphophorus. Another phylogenetically more widespread and older male trait is the gonopodium, an intromittent organ found in all poeciliid fishes, that is derived from a modified anal fin. Despite many evolutionary and behavioral studies on both traits, little is known so far about the molecular mechanisms underlying their development. By investigating transcriptomic changes (utilizing a RNA-Seq approach) in response to testosterone treatment in the swordtail fish, Xiphophorus hellerii, we aimed to better understand the architecture of the gene regulatory networks underpinning the development of these two evolutionary novelties. Large numbers of genes with tissue-specific expression patterns were identified. Among the sword genes those involved in embryonic organ development, sexual character development and coloration were highly expressed, while in the gonopodium rather more morphogenesis-related genes were found. Interestingly, many genes and genetic pathways are shared between both developing novel traits derived from median fins: the sword and the gonopodium. Our analyses show that a larger set of gene networks was co-opted during the development and evolution of the older gonopodium than in the younger, and morphologically less complex trait, the sword. We provide a catalog of candidate genes for future efforts to dissect the development of those sexually selected exaggerated male traits in swordtails.
While numerous experiments on NFAT were already performed with CD4+ T cells showing defective cytokine release and a reduced T helper cell development, no detailed studies existed for CD8+ T cells. From this point, we wanted to examine the impact of NFATc1 and c2 on the physiological functions of CD8+ T cells in vitro and in vivo. Therefore, we used a murine infection model with the bacteria Listeria monocytogenes and mice in which NFATc1 was specifically depleted in the T cell compartment.
Our first in vitro studies showed a typical NFATc1 and c2 nuclear translocation and changes on mRNA levels upon T cell activation similarly in CD4+ as well as in CD8+ T cells extracted from wild type mice. NFAT nuclear translocation is important for target gene activation and generation of effector functions. Stimulated T cell populations lacking NFATc1 and/or NFATc2 showed a markedly decreased expression of Th1/Tc1 cytokines, as e.g. IL 2 and IFNγ being important for the clearance of intracellular pathogens. From our in vitro model for the generation of allogenically reactive cytotoxic CD8+ T cells, we revealed a decreased killing and lytic granule-release capacity in Nfatc1 inactivated CD8+ T cells whereas NFATc2-/- cytotoxic T cells did not show an altered cytotoxic response compared to wild type cells.
Interestingly, we found lytic granules accumulated and mitochondria not getting translocated to the immunological synapse upon re-stimulation in NFATc1-deficient CD8+ T cells. Together with results showing the CsA insensitivity of the CTL killing/degranulation capacities, we assume that some major cellular processes are affected by NFATc1 which are not directly linked to the TCR-induced signal transduction cascade.
We also showed the importance of NFATc1 in T cells during intracellular infections with the bacteria Listeria monocytogenes in an in vivo mouse model. After five days, only few bacteria were detected in wt mice whereas high amounts of Listeria particles were extracted from livers of Nfatc1fl/fl x Cd4 cre mice. Although the reactivity towards the pathogen was similar in both groups, a decreased cytokine expression in NFATc1-/- CD8+ T cells was observed together with an altered memory cell generation.
Our results show the importance of NFATc1 in CD8+ T cells and give some clue for a possible connection to other basal cellular functions, as e.g. the formation of an immunological synapse.
The pro-apoptotic Bcl-2-family protein Bim belongs to the BH3-only proteins known as initiators of apoptosis. Recent data show that Bim is constitutively inserted in the outer mitochondrial membrane via a C-terminal transmembrane anchor from where it can activate the effector of cytochrome c-release, Bax. To identify regulators of Bim-activity, we conducted a search for proteins interacting with Bim at mitochondria. We found an interaction of Bim with Tom70, Tom20 and more weakly with Tom40, all components of the Translocase of the Outer Membrane (TOM). In vitro import assays performed on tryptically digested yeast mitochondria showed reduced Bim insertion into the outer mitochondrial membrane (OMM) indicating that protein receptors may be involved in the import process. However, RNAi against components of TOM (Tom40, Tom70, Tom22 or Tom20) by siRNA, individually or in combination, did not consistently change the amount of Bim on HeLa mitochondria, either at steady state or upon de novo-induction. In support of this, the individual or combined knockdowns of TOM receptors also failed to alter the susceptibility of HeLa cells to Bim-induced apoptosis. In isolated yeast mitochondria, lack of Tom70 or the TOM-components Tom20 or Tom22 alone did not affect the import of Bim into the outer mitochondrial membrane. In yeast, expression of Bim can sensitize the cells to Bax-dependent killing. This sensitization was unaffected by the absence of Tom70 or by an experimental reduction in Tom40. Although thus the physiological role of the Bim-TOM-interaction remains unclear, TOM complex components do not seem to be essential for Bim insertion into the OMM. Nevertheless, this association should be noted and considered when the regulation of Bim in other cells and situations is investigated.
LINC complexes are evolutionarily conserved nuclear envelope bridges, physically connecting the nucleus to the peripheral cytoskeleton. They are pivotal for dynamic cellular and developmental processes, like nuclear migration, anchoring and positioning, meiotic chromosome movements and maintenance of cell polarity and nuclear shape. Active nuclear reshaping is a hallmark of mammalian sperm development and, by transducing cytoskeletal forces to the nuclear envelope, LINC complexes could be vital for sperm head formation as well. We here analyzed in detail the behavior and function of Sun4, a bona fide testis-specific LINC component. We demonstrate that Sun4 is solely expressed in spermatids and there localizes to the posterior nuclear envelope, likely interacting with Sun3/Nesprin1 LINC components. Our study revealed that Sun4 deficiency severely impacts the nucleocytoplasmic junction, leads to mislocalization of other LINC components and interferes with the formation of the microtubule manchette, which finally culminates in a globozoospermia-like phenotype. Together, our study provides direct evidence for a critical role of LINC complexes in mammalian sperm head formation and male fertility.
Rhodopsins are membrane-embedded photoreceptors found in all major taxonomic kingdoms using retinal as their chromophore. They play well-known functions in different biological systems, but their roles in fungi remain unknown. The filamentous fungus Fusarium fujikuroi contains two putative rhodopsins, CarO and OpsA. The gene carO is light-regulated, and the predicted polypeptide contains all conserved residues required for proton pumping. We aimed to elucidate the expression and cellular location of the fungal rhodopsin CarO, its presumed proton-pumping activity and the possible effect of such function on F. fujikuroi growth. In electrophysiology experiments we confirmed that CarO is a green-light driven proton pump. Visualization of fluorescent CarO-YFP expressed in F. fujikuroi under control of its native promoter revealed higher accumulation in spores (conidia) produced by light-exposed mycelia. Germination analyses of conidia from carO\(^{-}\) mutant and carO\(^{+}\) control strains showed a faster development of light-exposed carO-germlings. In conclusion, CarO is an active proton pump, abundant in light-formed conidia, whose activity slows down early hyphal development under light. Interestingly, CarO-related rhodopsins are typically found in plant-associated fungi, where green light dominates the phyllosphere. Our data provide the first reliable clue on a possible biological role of a fungal rhodopsin.
G-protein-coupled receptors (GPCRs) are typically regarded as chemosensors that control cellular states in response to soluble extracellular cues. However, the modality of stimuli recognized through adhesion GPCR (aGPCR), the second largest class of the GPCR superfamily, is unresolved. Our study characterizes the Drosophila aGPCR Latrophilin/dCirl, a prototype member of this enigmatic receptor class. We show that dCirl shapes the perception of tactile, proprioceptive, and auditory stimuli through chordotonal neurons, the principal mechanosensors of Drosophila. dCirl sensitizes these neurons for the detection of mechanical stimulation by amplifying their input-output function. Our results indicate that aGPCR may generally process and modulate the perception of mechanical signals, linking these important stimuli to the sensory canon of the GPCR superfamily.